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Abstract
Antipsychotic drugs fail to achieve adequate response in 30–50% of treated patients and about 50% of them develop
severe and lasting side effects. Treatment failure results in poorer prognosis with devastating repercussions for the
patients, carers and broader society. Our study evaluated the clinical benefits of a pharmacogenetic intervention for
the personalisation of antipsychotic treatment. Pharmacogenetic information in key CYP polymorphisms was used to
adjust clinical doses in a group of patients who started or switched treatment with antipsychotic drugs (PharmG+,
N= 123), and their results were compared with those of a group of patients treated following existing clinical guides
(PharmG−, N= 167). There was no evidence of significant differences in side effects between the two arms. Although
patients who had their antipsychotic dose adjusted according to CYPs polymorphisms (PharmG+) had a bigger
reduction in side effects than those treated as usual (PharmG−), the difference was not statistically significant (p > 0.05
for all comparisons). However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or
PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG−
patients (p= 0.02, p= 0.05 and p= 0.01, respectively). PharmG+ clozapine treated patients with CYP1A2 or CYP2C19
UM and PMs variants also showed higher reductions in UKU scores than PharmG− clozapine patients in general.
However, those differences were not statistically significant. Pharmacogenetic interventions may improve the safety of
antipsychotic treatments by reducing associated side effects. This intervention may be particularly useful when
considering treatment with antipsychotics with one major metabolic pathway, and therefore more susceptible to be
affected by functional variants of CYP enzymes.
Introduction
Antipsychotic drugs are widely used for the treatment
of severe mental illness including schizophrenia, bipolar
disorder and major depression. However, 30–50% of
treated patients fail to respond adequately and about
50% of them develop severe and lasting side effects.
Treatment failure results in poorer prognosis with
devastating repercussions for the patients, carers and
broader society. The reasons for treatment failure are
unclear and ‘trial and error' naturalistic strategies are
used to select drug type and clinical doses for each
patient.
Growing evidence indicates that genetic factors play a
critical role in determining the clinical outcome of anti-
psychotic treatment1,2. Several genetic polymorphisms
have been identified in drug metabolic enzymes that
influence metabolising rates and clinical outcome. Cyto-
chrome P450 enzymes, responsible for the bio-
transformation of more than 85% of existing drugs, may
contain genetic variants that result in poor, intermediate,
extensive or ultra-rapid metabolic rates3,4. Individuals
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with slow metabolising CYP variants are prone to adverse
reactions, and require lower doses, whilst patients with
ultra-rapid metabolising CYP variants require higher
doses to obtain therapeutic response. CYPs are respon-
sible for the biotransformation of widely used anti-
psychotics such as clozapine (CYP1A2 and CYP2C19),
olanzapine (CYP1A2), risperidone and haloperidol
(CYP2D6), quetiapine and ziprasidone (CYP3A5)
amongst others5,6. The direct correlation between pre-
sence of slow metabolising CYP variants and
antipsychotic-induced adverse reactions is well docu-
mented, although their influence on the level of efficacy in
less clear7,8. It has been suggested that the adjustment of
clinical doses according to the CYP genetic profile (pre-
sence of functional polymorphisms) of patients has the
potential to significantly improve the efficacy (15%) and
safety (25% reduction in side effects) of pharmacological
treatments9.
There are several commercially available pharmacoge-
netic tests that interrogate CYP functional polymorph-
isms, which can be potentially useful for the
personalisation of antipsychotic drugs10. However, their
use in clinical settings is minimal. Recent studies have
proven the benefits of using pharmacogenetic information
for the personalisation of treatment in psychiatry. CYPs,
UGTs and multidrug resistance 1 (MDR1) genotyping for
antidepressant dose adjustment improves remission11.
The use of commercial tests interrogating key CYP
polymorphisms and serotonin genes resulted in improved
response to antidepressants12–15. A recent study in elderly
patients treated with antidepressants and antipsychotics
according to their pharmacogenetic profile had a sig-
nificant decrease in hospitalisations and emergency
department visits16. Pharmacogenetic-guided prescription
of antidepressants also resulted in improved adherence
and reduced pharmacy costs17,18. However, most studies
performed to date have focused on antidepressant medi-
cations. It is not yet sufficiently established the clinical
and economic benefits of introducing pharmacogenetic
interventions (PIs) for the improvement of antipsychotic
treatment. In addition, rapid testing protocols that deliver
clear recommendations on antipsychotic choice and dose
are required to increase the implementation of pharma-
cogenetics in clinical practice.
The aim of this study was to evaluate the clinical ben-
efits of a PI for the personalisation of antipsychotic
treatment. Pharmacogenetic information in key CYP
polymorphisms was used to adjust clinical doses in a
group of patients who started or switched treatment with
antipsychotic drugs, and their results were compared with
those of a group of patients treated following existing
clinical guides. We obtained encouraging results indicat-
ing that pharmacogenetic-guided antipsychotic prescrip-
tion may increase the safety of antipsychotic treatments.
Materials and methods
Description of sample
Two hundred and ninety patients with a diagnosis of
schizophrenia, schizoaffective or delusional disorders
(according to DSM-5) and requiring antipsychotic treat-
ment completed the study. Patients were recruited in the
mental health wards of three hospitals (Hospital Clínic
and Hospital de la Santa Creu i Sant Pau, Barcelona;
Hospital Universitario, Granada) and were mostly out-
patients. Patients were randomly selected for PI (PharmG
+ arm) or treatment as usual (PharmG− arm). Rando-
misation was conducted using a web programme (www.
randomiser.org). Pharmacogenetic arm (PharmG+): 123
patients were genotyped using a pharmacogenetic test at
the beginning of their treatment with a new antipsychotic
and clinical doses were adjusted accordingly when
required (PharmG+). Naturalistic arm (PharmG−): 167
patients were treated as usual following standard clinical
practices. This sample has a statistical power > 95% to
detect genetic associations with a medium effect size (f=
0.25, α error= 0.05, calculated with GPower version
3.0.10).
Response assessment
The positive and negative syndrome scale for schizo-
phrenia (PANSS19) and the UKU-side effect rating scale
(UKU-SERS20) scores were obtained in all patients at the
beginning and after 12 weeks to assess the efficacy and
safety of the treatment. PANSS and UKU values were
scored by trained psychiatrists who were blind to the
patients' pharmacogenetic arm. Within each participating
hospital, the same psychiatrist evaluated the pre and post
treatment patient status for both arms. Adherence was
confirmed by plasma levels at week 12 of treatment.
Table 1 summarises the clinical and demographic data of
the study samples. All participants gave informed consent
to the study, which was approved by the local ethics
committees.
Biological samples
Whole blood samples were collected from all partici-
pants at the time of recruitment. DNA was obtained using
commercial kits (QIAmp DNA mini Kit, Qiagen) within
hours of blood extraction and was immediately sent for
pharmacogenetic testing (PharmaG+ patients) or stored
at −80 °C until required.
Pharmacogenetic intervention
A commercial pharmacogenetic test (Brainchip,
Brainco, Bilbao, Spain) was used to characterise common
and functional polymorphisms in CYP1A2, CYP2D6,
CYP2C19 and CYP3A5 enzymes, the main metabolic
pathways of currently available antipsychotics. Table 2
summarises the list of key CYP polymorphisms genotyped
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that included the most frequently detected in Caucasian
populations21. A DNA sample from PharmG+ patients
was obtained at the time of initiating or changing anti-
psychotic treatment and sent to Brainco for character-
isation with the Brainchip array. Results were returned
within 1–2 weeks of extraction to the responsible clin-
ician, and dose adjustments, if necessary, were performed
according to the study protocol. Patients were maintained
on antipsychotic monotherapy during the duration of the
study.
Dose adjustment protocol
Patients were recruited when starting treatment with an
antipsychotic or when a change in their antipsychotic
treatment was required. All patients (PharmG+ and
PharmG−) were informed of the study and were blind to
the PI. No pharmacogenetic information was provided to
the patients, nor were they told if changes in their med-
ication had been required as a result. At the time of the
study, there were no clinical guidelines on the level of
dose adjustment required for patients with CYP func-
tional polymorphisms. The clinical recommendations
(dose adjustments) used in the study were decided by the
clinical teams at the beginning of the project and are
summarised in Table 3. Doses were adjusted according to
main metabolic pathways:5,6 clozapine doses were adjus-
ted according to the genotypic variants observed in
CYP1A2 and CYP2C19; olanzapine doses were adjusted
according to CYP1A2 polymorphisms; risperidone, aripi-
prazole, haloperidol, pimozide and trifluoperazine doses
were adjusted according to CYP2D6 polymorphisms;
finally, quetiapine and ziprasidone doses were adjusted










Male 63 (51.2%) 94 (56.3%) 157 (54.1%)
Female 60 (48.8%) 73 (43.7%) 133 (45.9%)
Age
Mean (SD) (years) 46.11 ± 13.7 48.68 ± 13.46
Diagnosis
Schizophrenia 86% 69% 76%
Schizoaffective 5% 4% 4%
Delusional disorder 9% 27% 20%
Treatment
Drug
Clozapine 43 (35%) 88 (52.7%) 131 (45.2%)
Risperidone 16 (13%) 20 (12%) 36 (12.4%)
Olanzapine 25 (20.3%) 14 (8.4%) 39 (13.4%)
Paliperidone 16 (13%) 22 (13%) 38 (13.1%)
Aripiprazole 7 (5.7%) 13 (7.8%) 20 (6.9%)
Quetiapine 11 (8.9%) 5 (3%) 16 (5.5%)
Ziprasidone 1 (0.8%) 2 (1.2%) 3 (1%)
Trifluoperazine 1 (0.8%) 1 (0.6%) 2 (0.7%)
Haloperidol 1 (0.8%) 1 (0.6%) 2 (0.7%)
Asenapine 1 (0.8%) 1 (0.6%) 2 (0.7%)
Pimozide 1 (0.8%) 0 1 (0.3%)
Dose (olanzapine equivalent)
Average dose (SD) 11.57 ± 7.28 10.65 ± 5.70
PANSS basal scores
Mean (SD) 99.23 ± 18.08 91.55 ± 17.55
UKU basal scores
Mean (SD) 9.15 ± 5.98 6.83 ± 5.40
Table 2 Key CYP polymorphisms genotyped in the
samples
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according to CYP3A5 genetic variants. Paliperidone and
asenapine doses were not adjusted unless they were given
in combination with a second antipsychotic, in which case
the second antipsychotic was used as a guide for adjust-
ment. According to this protocol, N= 55 PharmG+
patients required dose adjustments of the antipsychotic
drug received. Despite adjustments, clinical doses
remained within recommended ranges in both arms.
Genotypic characterisation of samples
All patients (PharmG+ and PharmG−, N= 290) were
genotyped for the key CYP functional polymorphisms
included in the pharmacogenetic array using iPlex® Gold
chemistry and the MassARRAY platform (CEGEN-PRB2-
ISCIII, University of Santiago de Compostela, Spain) and
TaqMan probes and technology for the CNVs (University
of Granada). High-throughput genotyping results coin-
cided with those obtained with the commercial array in
overlapping samples and polymorphisms.
Statistical analyses
Linear regression models to assess the influence of the
PI were calculated considering level of response and side
effects improvement as dependent variables. The PI
(study arm PharmG+ or PharmG−) was included as a
predictor variable and drug, gender, dose (olanzapine
equivalent), age of patients and PI as additional covari-
ables. All analyses were performed using the statistic
package SPSS (version 22, IBM).
Results
Tables 4 and 5 summarise the results of the statistical
analyses. The CYP minor allele frequencies observed
agreed with those described in European populations21.
Despite randomisation during the recruitment, differ-
ences were observed in the distribution of treatments (p
= 0.01) and in the severity of symptoms (p= 0.002)
between arms (see Table 1). To minimise these differ-
ences, the PANSS or UKU score differences (basal scores
− scores at 12 weeks of treatment) were considered as the
dependent variables. In addition, treatment (antipsychotic
drug) was one of the covariates considered in the
regression model.
No significant differences in variation in PANSS scores
were observed between PharmG+ (26.81 ± 1.3 score
reduction after 12 weeks, on average) and PharmG−
patients (26.6 ± 1 score reduction after 12 weeks, on
average) (see Table 4). Linear model regression con-
sidering PI (PharmG+ or PharmG− arm), age, gender,
dose (olanzapine equivalent) and drug as covariates con-
firmed this observation (model χ2= 6.72, df= 5, p= 0.24,
PI Wald coefficient= 0.04, p= 0.84). Similarly, no sig-
nificant differences in PANSS scores improvement were
observed between PharmG+ and PharmG− patients
treated with clozapine (29.36 ± 2.3 vs 26 ± 1.4, respec-
tively; model χ2= 8.54, df= 4, p= 0.08, Wald coefficient
for PI= 1.32, p= 0.25). Analyses within the subgroup of
patients treated with drugs mainly metabolised by the
enzyme CYP2D6 (risperidone, haloperidol, aripiprazole,
pimozide and trifluoperazine) also showed no differences
with PharmG+ and PharmG− patients showing similar
variations in PANSS scores (24.33 ± 3 vs 26.47 ± 2). This
difference was not statistically significant (χ2= 2.90, df=
5, p= 0.72 and Wald= 0.34, p= 0.56 for model and PI,
respectively). When analysing patients with functional
variants in CYP1A2, CYP2D6 and/or CYP2C19 (N= 155),
no differences were observed between PharmG+ and
PharmG− patients in PANSS improvement, nor was it
observed in the subgroups of patients treated with clo-
zapine (p > 0.05 for all comparisons, see Table 5). How-
ever, there was a significant difference when analysing
PANSS score improvement between PharmG+ patients
(26.6 ± 3.5) and PharmG− patients (28.63 ± 3.7) treated
with CYP2D6 substrates. This significant difference was
Table 3 Recommended adjustment of clinical doses for patients undergoing pharmacogenetic intervention (PharmG+)
Antipsychotic Standard
clinical dose
CYP1A2 CYP2D6 CYP2C19 CYP3A5
PM IM UM PM IM UM PM IM PM IM UM
Clozapine 150–900mg/day <25–50% NC >25–30% <25–30% NC
Olanzapine 7.5–30 mg/day <25–50% NC >25–30%
Risperidone 3–12 mg/day <25–30% Gradual >25–30%
Haloperidol 10–20 mg/day <50% <10–20% >25–30%
Aripiprazole 10–30 mg/day <25–50% Gradual >25–30%
Quetiapine 300–750mg/day <25–50% <10–20% >25–30%
Ziprasidone 80–160mg/day <5–50% <10–20% >25–30%
Gradual: 5–10% reduction every 3 days (up to 30% reduction) depending on side effects
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mainly caused by patients' gender (Wald= 6.25, p= 0.01)
and dose (Wald= 6.25, p= 0.01) and not by the PI (Wald
= 1.03, p= 0.31).
Analyses of improvement in side effects after 12 weeks of
treatment (UKU basal scores−UKU scores after 12 weeks)
revealed a slightly higher improvement (bigger difference in
UKU score reduction) in PharmG+ than in PharmG−
patients in general, especially in the UKU psychic subscales
(Table 4). However, the contribution of the PI to these
improvements was not statistically significant (p > 0.05 for
all comparisons). Analyses of patients with functional var-
iants in CYP1A2, CYP2D6 or CYP2C19 revealed clearer
improvements in the profile of side effects in the PharmG+
patients in comparison to PharmG− patients. Psychic side
effects were further reduced in PharmG+ patients (2.40 ±
0.41) in comparison to PharmG− patients (1.21 ± 0.37;
χ2= 10.90, p= 0.05 and Wald= 3.30, p= 0.07 for model
and PI, respectively). The PI was significantly associated to
improvements in total (6.92 improvement in PharmG+ vs
1.27 in PharmG−, Wald= 5.56, p= 0.02), psychic (2.50 vs
0.53 improvement, Wald= 3.96, p= 0.05) and other UKU
side effects (1.08 vs −0.3, Wald= 6.19, p= 0.01) in the
subgroup of patients treated with CYP2D6 substrates (see
Table 5).
Discussion
Despite growing evidence showing the influence of
genetic factors on antipsychotic treatment efficacy, phar-
macogenetic information is rarely used in clinical settings
for the personalisation of treatment. Several studies have
shown that most clinicians and patients are in favour of
PIs22–24. However, the scarce evidence on the clinical and
economic benefits of PIs in psychiatry hamper their
implementation in clinical practice. In this study, we
investigated the clinical benefits of using genetic infor-
mation in CYP metabolising enzymes for the adjustment
of clinical doses of a variety of commonly used anti-
psychotics and compared the results with those of
patients treated as usual.
Several commercial pharmacogenetic tests are available
for use in psychiatry25. Most of them interrogate key func-
tional polymorphisms in drug metabolising enzymes.
Table 4 Summary of statistical analyses in all samples


















Difference in PANSS average 26.81+ 1.3 26.60+ 1 29.36+ 2.3 26.0+ 1.4 24.33+ 3.0 26.47+ 2.0
Model χ2 (p value) 6.72 (0.24) 8.54 (0.08) 2.90 (0.72)
PI Wald (p value) 0.04 (0.84) 1.32 (0.25) 0.34 (0.56)
Difference in UKU scores 3.62 ± 0.66 3 ± 0.56 3.81 ± 1.10 2.67 ± 1.03 4.04 ± 1.34 2.69 ± 1.11
Model χ2 (p value) 10.19 (0.07) 5.67 (0.23) 2.79 (0.73)
PI Wald (p value) 0.40 (0.53) 0.002 (0.97) 0.38 (0.54)
Difference in psychic SE 2.02 ± 0.36 1.26 ± 0.30 1.84 ± 0.63 1.38 ± 0.52 1.60 ± 0.72 0.53 ± 0.53
Model χ2 (p value) 10.38 (0.07) 3.26 (0.52) 7.71 (0.17)
PI Wald (p value) 1.53 (0.22) 0.03 (0.86) 0.64 (0.42)
Difference in neurological SE 0.87 ± 0.20 0.94 ± 0.25 0.98 ± 0.32 0.54 ± 0.51 1.04 ± 0.48 1.25 ± 0.56
Model χ2 (p value) 12.49 (0.03) 12.65 (0.01) 2.01 (0.85)
PI Wald (p value) <0.01 (0.99) 0.01 (0.91) 0.08 (0.78)
Difference autonomic SE 0.32 ± 0.26 0.17 ± 0.12 0.16 ± 0.51 0.37 ± 0.37 0.71 ± 0.45 0.28 ± 0.16
Model χ2 (p value) 4.09 (0.54) 4.42 (0.35) 10.03 (0.07)
PI Wald (p value) 0.35 (0.56) 0.47 (0.49) 0.93 (0.33)
Difference in other side
effects
0.54 ± 0.24 0.52 ± 0.23 0.93 ± 0.30 0.38 ± 0.41 0.56 ± 0.30 0.44 ± 0.29
Model χ2 (p value) 9.67 (0.09) 2.53 (0.64) 2.45 (0.78)
PI Wald (p value) 0.003 (0.95) 1.32 (0.25) 0.07 (0.79)
PI pharmacogenetic intervention, SE side effects
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However, several of these tests include other polymorphisms
of unclear clinical value. We used a pharmacogenetic test
that gives detailed information on CYPs functional poly-
morphisms. CYPs genotypes were used for dose adjust-
ments, whilst the additional polymorphisms genotyped by
the test were not considered for the intervention. This
alternative information should not be considered until
confirmation of their relevance is obtained, as it may hamper
the clinical value and implementation of pharmacogenetic
tests26. In the case of antipsychotics, the most robust results
are those that associate CYP functional polymorphisms with
adverse reactions7, whereas other polymorphisms in
dynamic genes have been also proven to be useful for the
improvement of antidepressant medication27.
Our results showed that a PI consisting in adjustments
of clinical doses in patients with CYP alterations did not
have a significant influence on the level of efficacy of
antipsychotic treatments (p > 0.05 in all comparisons).
This was somehow expected. Given the complex phar-
macodynamic profile on antipsychotic drugs, treatment
success may be influenced not only by drug
pharmacokinetics, but also by pharmacodynamic inter-
actions with the many receptors targeted by currently
available antipsychotic drugs. Therefore, the possible
influence of altered metabolism on drug efficacy may be
diluted. Previous genetic association studies have failed to
find a clear association between CYPs functional poly-
morphisms and antipsychotic treatment response8.
Nevertheless, strong evidence supports the influence of
CYPs variants on the development of drug-induced
adverse reactions7,22,28–30. Interestingly, we found that
patients who had their antipsychotic dose adjusted
according to key polymorphisms (PharmG+) had a bigger
reduction in side effects than those treated as usual
(PharmG−). This finding was not statistically significant
when investigating all the participants in the study.
However, when looking at the subgroup of patients who
had functional variants in the CYPs responsible for the
metabolism of their prescribed antipsychotic, the results
were clearer. Our PI was particularly useful in the
reduction of psychic symptoms (p= 0.07) in patients with
CYPs functional variants. The subgroup of patients
Table 5 Summary of statistical analyses in individuals with functional variants in relevant CYPs


















Difference in PANSS average 26.88+ 1.4 25.92+ 1.3 30.10+ 3 24.74+ 2 26.58+ 3.5 28.63+ 3.7
Model χ2 (p value) 1.68 (0.89) 5.19 (0.27) 12.88 (0.03)
PI Wald (p value) 0.16 (0.69) 1.78 (0.18) 1.03 (0.31)
Difference in UKU scores 4.20 ± 0.76 3.01 ± 0.66 4.24 ± 1.39 3.08 ± 1.25 6.92 ± 2.09 1.27 ± 1.78
Model χ2 (p value) 8.80 (0.12) 3 (0.56) 8.20 (0.15)
PI Wald (p value) 1.23 (0.27) 0.02 (0.89) 5.56 (0.02)
Difference in psychic SE 2.40 ± 0.41 1.21 ± 0.37 2.14 ± 0.82 1.42 ± 0.70 2.50 ± 1.14 0.53 ± 0.77
Model χ2 (p value) 10.90 (0.05) 1.20 (0.88) 10.83 (0.06)
PI Wald (p value) 3.30 (0.07) 0.14 (0.71) 3.96 (0.05)
Difference in neurological SE 0.99 ± 0.24 1.08 ± 0.26 1.24 ± 0.40 0.67 ± 0.67 1.67 ± 0.64 0.53 ± 0.76
Model χ2 (p value) 11.27 (0.05) 15.91 (0.003) 3.63 (0.60)
PI Wald (p value) 0.01 (0.91) 0.03 (0.87) 1.67 (0.20)
Difference autonomic SE 0.31 ± 0.29 0.20 ± 0.13 0.07 ± 0.64 0.75 ± 0.41 1.33 ± 0.91 0.13 ± 0.13
Model χ2 (p value) 3.04 (0.69) 2.14 (0.71) 5.13 (0.40)
PI Wald (p value) 0.22 (0.64) 0.66 (0.42) 1.29 (0.26)
Difference in other side
effects
0.59 ± 0.28 0.45 ± 0.29 0.86 ± 0.39 0.25 ± 0.74 1.08 ± 0.57 −0.3 ± 0.41
Model χ2 (p value) 7.39 (0.19) 6.20 (0.19) 7.99 (0.16)
PI Wald (p value) 0.10 (0.75) 0.08 (0.78) 6.19 (0.01)
PI pharmacogenetic intervention, SE side effects
Arranz et al. Translational Psychiatry           (2019) 9:177 Page 6 of 8
treated with CYP2D6 substrates (risperidone, haloperidol,
aripiprazole, pimozide and trifluoperazine) that were
carriers of CYP2D6 UMs or PMs variants clearly benefited
from the intervention: model regression analyses showed
that the PI resulted in a significant improvement in global,
psychic and other UKU side effects (p= 0.02, p= 0.05 and
p= 0.01, respectively). PharmG+ clozapine treated
patients also showed higher reductions in UKU scores
than PharmG− clozapine patients in general. However,
those differences were not statistically significant, even
when considering patients with CYP1A2 or CYP2C19 UM
and PMs variants (p > 0.05 in all comparisons). These
results suggest that a PI would be particularly useful when
considering treatment with antipsychotic drugs with one
main CYP pathway, where the influence of UMs and PMs
variants should be more evident.
Previous studies on the benefits of PIs in psychiatry have
focused mainly on antidepressant treatments. Several studies
have proven the clinical value of a commercial array com-
bining genetic information in metabolic enzymes (CYP1A2,
CYP2D6 and CYP2C19) and antidepressant targets (ser-
otonin transporter, SLC6A4 and serotonin receptor 2A,
HTR2A). Patients whose antidepressant drug and dose were
selected according to the array polymorphisms showed
better symptom improvement than patients treated as
usual12,13. Similar results were found in a recent study in
Spanish patients, also using a commercial kit that included
CYPs, multidrug resistance 1 (MDR1 o ABCB1) and other
target variants1. A study using the same commercial kit in a
retrospective study on psychiatric patients receiving a variety
of psychotropic drugs observed that those patients who had
followed the test recommendations showed better treatment
response31. A recent study in which clinicians were provided
pharmacogenetic information based on CYP2D6 and
CYP2C19 variants to adjust antipsychotic and anti-
depressant treatments in 80 psychiatric patients suggested a
favourable opinion on the outcome of the intervention,
although no control group was considered in the study32.
Interestingly, Herbid et al. showed in a previous study that
the adjustment of clinical doses according to CYP2D6 and
CYP2C19 polymorphisms resulted in a reduction of treat-
ment costs in schizophrenia patients showing poor or ultra-
rapid metabolism33. However, no previous study has focused
on the prospective evaluation of clinical improvement when
using pharmacogenetics for the adjustment of antipsychotic
treatments. To our knowledge, our findings are the first
evidence of the clinical benefits obtained by a pharmaco-
genetic selection of antipsychotic clinical doses in compar-
ison to naturalistic practices.
Our study has several limitations. Despite randomisa-
tion during recruitment, antipsychotic treatments and
severity of symptoms were not evenly distributed in the
study arms (PharmG+ and PharmG−). To minimise the
effect of these differences on results, both factors
(antipsychotic treatment and basal symptom severity)
were included as covariates in the analyses. Sample size
was dimed sufficient for the study aims. However, the
limited number of patients carrying CYP functional
polymorphisms did not allow the investigation of func-
tional groups (UMs and PMs separately). In addition, the
variety of treatments used in the study hampered the
investigation of individual drugs. Nevertheless, we per-
formed analyses on the subgroups of patients carrying
CYPs functional variants (either UMs or PMs), and
investigated the two largest antipsychotic groups within
the study (clozapine and CYP2D6 substrates). Finally, a
CYP2D6*17 polymorphism with reduced activity was not
investigated in our study as it was not included in the
array used for the PI. However, the reported frequency of
this allele in the Spanish population is very low (0.0093)
and should not greatly influence the results34.
In summary, although we found no evidence of greater
efficacy, a PI may improve the safety profile of anti-
psychotic treatments in patients presenting poor or ultra-
rapid CYP variants. The PI described in our study may be
particularly useful when considering treatment with
antipsychotics with one major metabolic pathway, and
therefore more susceptible to be affected by functional
variants of CYP metabolising enzymes.
Acknowledgements
We are extremely grateful to allparticipants. We thank the Spanish Ministry of
Economy, Industry, and the European Funds for Regional Development (Fondo
Europeo de Desarrollo Regional, FEDER) for their support. We are indebted to
the IDIBAPS Biobank, integrated in the Spanish National Biobank Network, for
samples and data procurement. This research was funded by grants from the
Institute Carlos III (FIS PI11/02006; FIS PI16/01029). A.G.-R. was partially funded
by a private grant from the Jové family. Genotyping was partially conducted by
the CEGEN-PRB2-ISCIII node, which is supported by grant PT13/001, ISCIII-
SGEFI/FEDER.
Author details
1Fundació Docència i Recerca Mútua Terrassa, Terrassa, Spain. 2Centro de
Investigación en Red de Salud Mental, CIBERSAM, Madrid, Spain. 3Department
of Mental Health, Parc Taulí University Hospital Sabadell, Barcelona, Spain.
4Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona,
Spain. 5Barcelona Clinic Schizophrenia Unit (BCSU), Neurosciences Institute,
Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain.
6Department of Psychiatry, University of Granada, Granada, Spain. 7Department
of Biologia Evolutiva, Ecologia i Ciències Ambientals, Facultat de Biologia,
Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain.
8Pharmacology and Toxicology Unit, Department of Biochemistry and
Molecular Genetics, Hospital Clinic, Barcelona, Spain. 9Genetics Department,
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Conflict of interest
M.J.A. consulted for Brainco, the company commercialising the
pharmacogenetic test used in the study. However, the company closed in
2014 and did not influence in any way the results of this study. R.C. has
received honoraria or travel grants from Janssen, Pfizer, Ferrer, Adamed and
Lundbeck-Otsuka. A.G.-R. has received honoraria and/or travel grants from
Janssen, Pfizer, Ferrer and Lundbeck-Otsuka.
Arranz et al. Translational Psychiatry           (2019) 9:177 Page 7 of 8
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 15 January 2019 Revised: 9 May 2019 Accepted: 31 May 2019
References
1. Arranz M., Perez-Blanco J. & Arias B. Pharmacogenetics of the efficacy of
antipsychotic drugs in schizophrenia. in Genetic Influences on Response to Drug
Treatment for Major Psychiatric Disorders (eds Rybakowski J. & Serretti A.)
(Springer International Publishing, Switzerland, 2016).
2. Pouget, J. G., Shams, T. A., Tiwari, A. K. & Müller, D. J. Pharmacogenetics and
outcome with antipsychotic drugs. Dialogues Clin. Neurosci. 16, 555–566
(2014).
3. Bertilsson, L. Metabolism of antidepressant and neuroleptic drugs by cyto-
chrome p450s: clinical and interethnic aspects. Clin. Pharm. Ther. 82, 606–609
(2007).
4. Zanger, U. M., Turpeinen, M., Klein, K. & Schwab, M. Functional pharmaco-
genetics/genomics of human cytochromes P450 involved in drug bio-
transformation. Anal. Bioanal. Chem. 392, 1093–1108 (2008).
5. Arranz, M. J. & de Leon, J. Pharmacogenetics and pharmacogenomics of
schizophrenia: a review of last decade of research. Mol. Psychiatry 12, 707–747
(2007).
6. Ravyn, D., Ravyn, V., Lowney, R. & Nasrallah, H. A. CYP450 pharmacogenetic
treatment strategies for antipsychotics: a review of the evidence. Schizophr.
Res. 149, 1–14 (2013).
7. Fleeman, N. et al. The clinical effectiveness and cost-effectiveness of testing for
cytochrome P450 polymorphisms in patients with schizophrenia treated with
antipsychotics: a systematic review and economic evaluation. Health Technol.
Assess. 14, 1–157 (2010).
8. Fleeman, N. et al. Cytochrome P450 testing for prescribing antipsychotics in
adults with schizophrenia: systematic review and meta-analyses. Pharm. J. 11,
1–14 (2011).
9. Ingelman-Sundberg, M. Pharmacogenetics of cytochrome P450 and its
applications in drug therapy: the past, present and future. Trends Pharm. Sci.
25, 193–200 (2004).
10. Bousman, C. A. & Hopwood, M. Commercial pharmacogenetic-based deci-
sion-support tools in psychiatry. Lancet Psychiatry 3, 585–590 (2016).
11. Singh, A. B. Improved antidepressant remission in major depression via a
pharmacokinetic pathway polygene pharmacogenetic report. Clin. Psycho-
pharmacol. Neurosci. 13, 150–156 (2015).
12. Altar, C. A. et al. Clinical validity of cytochrome P450 metabolism and serotonin
gene variants in psychiatric pharmacotherapy. Int. Rev. Psychiatry 25, 509–533
(2013).
13. Hall-Flavin, D. K. et al. Using a pharmacogenomic algorithm to guide the
treatment of depression. Transl. Psychiatry 2, e172 (2012).
14. Pérez, V. et al. Efficacy of prospective pharmacogenetic testing in the treat-
ment of major depressive disorder: results of a randomized, double-blind
clinical trial. BMC Psychiatry 17, 250 (2017).
15. Rosenblat, J. D., Lee, Y. & McIntyre, R. S. Does pharmacogenomic testing
improve clinical outcomes for major depressive disorder? A systematic review
of clinical trials and cost-effectiveness studies. J. Clin. Psychiatry 78, 720–729
(2017).
16. Brixner, D. et al. The effect of pharmacogenetic profiling with a clinical deci-
sion support tool on healthcare resource utilization and estimated costs in the
elderly exposed to polypharmacy. J. Med. Econ. 19, 213–228 (2016).
17. Winner, J. G. et al. Combinatorial pharmacogenomic guidance for psychiatric
medications reduces overall pharmacy costs in a 1 year prospective evalua-
tion. Curr. Med. Res. Opin. 31, 1633–1643 (2015).
18. Fagerness, J. et al. Pharmacogenetic-guided psychiatric intervention asso-
ciated with increased adherence and cost savings. Am. J. Manag. Care 20,
e146–e156 (2014).
19. Kay, S. R., Fiszbein, A. & Opler, L. A. The positive and negative syndrome scale
(PANSS) for schizophrenia. Schizophr. Bull. 13, 261–276 (1987).
20. Lingjaerde, O., Ahlfors, U. G., Bech, P., Dencker, S. J. & Elgen, K. The UKU side
effect rating scale. A new comprehensive rating scale for psychotropic drugs
and a cross-sectional study of side effects in neuroleptic-treated patients. Acta
Psychiatr. Scand. Suppl. 334, 1–100 (1987).
21. Zhou, Y., Ingelman-Sundberg, M. & Lauschke, V. M. Worldwide distribution of
cytochrome P450 alleles: a meta-analysis of population-scale sequencing
projects. Clin. Pharm. Ther. 102, 688–700 (2017).
22. Müller, D. J., Kekin, I., Kao, A. C. & Brandl, E. J. Towards the implementation of
CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a
pharmacogenetic service clinic. Int. Rev. Psychiatry 25, 554–571 (2013).
23. Lanktree, M. B. et al. Positive perception of pharmacogenetic testing for
psychotropic medications. Hum. Psychopharmacol. 29, 287–291 (2014).
24. Walden, L. M. et al. Physicians’ opinions following pharmacogenetic testing for
psychotropic medication. Psychiatry Res. 229, 913–918 (2015).
25. Bousman, C. A., Jaksa, P. & Pantelis, C. Systematic evaluation of commercial
pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele
coverage and results reporting. Pharm. Genom. 27, 387–393 (2017).
26. de Leon, J. & Spina, E. What is needed to incorporate clinical pharmacogenetic
tests into the practice of psychopharmacotherapy? Expert Rev. Clin. Pharmacol.
9, 351–354 (2016).
27. Fabbri, C. et al. Consensus paper of the WFSBP Task Force on Genetics:
genetics, epigenetics and gene expression markers of major depressive dis-
order and antidepressant response. World J. Biol. Psychiatry 18, 5–28 (2017).
28. Lee, H. J. & Kang, S. G. Genetics of tardive dyskinesia. Int. Rev. Neurobiol. 98,
231–264 (2011).
29. Zackrisson, A. L., Lindblom, B. & Ahlner, J. High frequency of occurrence of
CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism
among suicide cases. Clin. Pharm. Ther. 88, 354–359 (2010).
30. Chaudhry, S. R. et al. Pharmacogenetic prediction of individual variability in
drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic poly-
morphisms. Curr. Drug Metab. 15, 711–718 (2014).
31. Espadaler, J., Tuson, M., Lopez-Ibor, J. M., Lopez-Ibor, F. & Lopez-Ibor, M. I.
Pharmacogenetic testing for the guidance of psychiatric treatment: a multi-
center retrospective analysis. CNS Spectr. 22, 315–324 (2017).
32. Walden L. M. et al. Genetic testing for CYP2D6 and CYP2C19 suggests
improved outcome for antidepressant and antipsychotic medication. Psy-
chiatry Res. pii: S0165-1781(17)31330-6. https://doi.org/10.1016/j.psychres.2018.
02.055. (2018). [Epub ahead of print].
33. Herbild, L., Andersen, S. E., Werge, T., Rasmussen, H. B. & Jürgens, G. Does
pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with
diagnoses within the schizophrenic spectrum reduce treatment costs? Basic
Clin. Pharm. Toxicol. 113, 266–272 (2013).
34. Naranjo, M. E. et al. High frequency of CYP2D6 ultrarapid metabolizers in Spain:
controversy about their misclassification in worldwide population studies.
Pharm. J. 16, 485–490 (2016).
Arranz et al. Translational Psychiatry           (2019) 9:177 Page 8 of 8
